We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Increased Level of Screening Drives Cancer IVD Sector

By Labmedica staff writers
Posted on 30 Jun 2008
The increased level of cancer screening, a public health priority as well as a healthcare cost priority, continues to drive basic testing techniques such as fecal occult blood testing. More...
Advances in pharmacodiagnostic technologies, genetic tests, and molecular tests, which determine tumor growth pathways in the evaluation of patients at risk, offer the potential to open new market niches.

The emergence of a new approach, which views cancer as a chronic disease has also been a boon for IVD developers. With advances in early screening and improved therapeutics, there is more need for cancer management and monitoring tests.

A Report Buyer (London, UK) report showed that the world market for in-vitro diagnostic (IVD) cancer tests is growing at nearly 11% annually and could reach US$8 billion by the end of 2012.

Report Buyer is a UK-based independent online store supplying business information. The website now carries over 70,000 business information products, including market reports, studies, books, and events.


Related Links:
Report Buyer

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.